Preclinical in vivo application of 152Tb-DOTANOC: a radiolanthanide for PET imaging

Müller, Cristina; Vermeulen, Christiaan; Johnston, Karl; Köster, Ulli; Schmid, Raffaella; Türler, Andreas; van der Meulen, Nicholas P. (2016). Preclinical in vivo application of 152Tb-DOTANOC: a radiolanthanide for PET imaging. EJNMMI research, 6(1), p. 35. Springer 10.1186/s13550-016-0189-4

art%3A10.1186%2Fs13550-016-0189-4.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (3MB) | Preview


Terbium has attracted the attention of researchers and physicians due to the existence of four medically interesting radionuclides, potentially useful for SPECT and PET imaging, as well as for α- and β−-radionuclide therapy. The aim of this study was to produce 152Tb (T 1/2 = 17.5 h, Eβ+av = 1140 keV) and evaluate it in a preclinical setting in order to demonstrate its potential for PET imaging. For this purpose, DOTANOC was used for targeting the somatostatin receptor in AR42J tumor-bearing mice.

152Tb was produced by proton-induced spallation of tantalum targets, followed by an online isotope separation process at ISOLDE/CERN. After separation of 152Tb using cation exchange chromatography, it was directly employed for radiolabeling of DOTANOC. PET/CT scans were performed with AR42J tumor-bearing mice at different time points after injection of 152Tb-DOTANOC which was applied at variable molar peptide amounts. 177Lu-DOTANOC was prepared and used in biodistribution and SPECT/CT imaging studies for comparison with the PET results.

After purification, 152Tb was obtained at activities up to ~600 MBq. Radiolabeling of DOTANOC was achieved at a specific activity of 10 MBq/nmol with a radiochemical purity >98 %. The PET/CT scans of mice allowed visualization of AR42J tumor xenografts and the kidneys, in which the radiopeptide was accumulated. After injection of large peptide amounts, the tumor uptake was reduced as compared to the result after injection of small peptide amounts. PET images of mice, which received 152Tb-DOTANOC at small peptide amounts, revealed the best tumor-to-kidney ratios. The data obtained with 177Lu-DOTANOC in biodistribution and SPECT/CT imaging studies confirmed the 152Tb-based PET results.

Production of 30-fold higher quantities of 152Tb as compared to the previously performed pilot study was feasible. This allowed, for the first time, labeling of a peptide at a reasonable specific activity and subsequent application for in vivo PET imaging. As a β+-particle-emitting radiolanthanide, 152Tb would be of distinct value for clinical application, as it may allow exact prediction of the tissue distribution of therapeutic radiolanthanides.

Item Type:

Journal Article (Original Article)


08 Faculty of Science > Department of Chemistry, Biochemistry and Pharmaceutical Sciences (DCBP)

UniBE Contributor:

Türler, Andreas


500 Science > 570 Life sciences; biology
500 Science > 540 Chemistry








Franziska Bornhauser-Rufer

Date Deposited:

24 Jan 2017 09:42

Last Modified:

05 Dec 2022 15:01

Publisher DOI:





Actions (login required)

Edit item Edit item
Provide Feedback